{"slideshow_credits": null, "snippet": "The company, which is facing inquiries over its drug-pricing policies, had previously delayed the release of its earnings. Its shares dropped sharply.", "abstract": "Valeant Pharmaceuticals shares drop over 50 percent after company releases earnings guidance and warns it may default on some of its debt; company says it now expects 2016 revenue of $11 billion to $11.2 billion, down from previous forecast of $12.5 billion to $12.7 billion.  ", "section_name": "Business Day", "print_page": "1", "document_type": "article", "byline": {"person": [{"firstname": "Katie", "role": "reported", "lastname": "THOMAS", "rank": 1, "organization": ""}], "original": "By KATIE THOMAS", "contributor": "Gretchen Morgenson and Alexandra Stevenson contributed reporting."}, "web_url": "http://www.nytimes.com/2016/03/16/business/valeant-q4-financial-2016-guidance.html", "lead_paragraph": "The company, which is facing inquiries over its drug-pricing policies, had previously delayed the release of its earnings. Its shares dropped sharply.", "headline": {"main": "Battered Valeant Stock Drops a Further 50% After Weak Guidance", "print_headline": "A Warning on Earnings by Valeant Sends Its Shares Into a Tailspin"}, "_id": "56e7f4b038f0d83d7cbf5024", "word_count": "813", "multimedia": [{"height": 126, "url": "images/2016/03/01/business/01VALEANTSUPERREFER/01VALEANTSUPERREFER-thumbWide.jpg", "legacy": {"wideheight": "126", "wide": "images/2016/03/01/business/01VALEANTSUPERREFER/01VALEANTSUPERREFER-thumbWide.jpg", "widewidth": "190"}, "subtype": "wide", "width": 190, "type": "image"}, {"height": 400, "url": "images/2016/03/01/business/01VALEANTSUPERREFER/01VALEANTSUPERREFER-articleLarge.jpg", "legacy": {"xlarge": "images/2016/03/01/business/01VALEANTSUPERREFER/01VALEANTSUPERREFER-articleLarge.jpg", "xlargewidth": "600", "xlargeheight": "400"}, "subtype": "xlarge", "width": 600, "type": "image"}, {"height": 75, "url": "images/2016/03/01/business/01VALEANTSUPERREFER/01VALEANTSUPERREFER-thumbStandard.jpg", "legacy": {"thumbnail": "images/2016/03/01/business/01VALEANTSUPERREFER/01VALEANTSUPERREFER-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "subtype": "thumbnail", "width": 75, "type": "image"}], "pub_date": "2016-03-16T00:00:00Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"name": "organizations", "value": "Valeant Pharmaceuticals International Inc", "is_major": "Y", "rank": "1"}, {"name": "subject", "value": "Company Reports", "is_major": "N", "rank": "2"}], "blog": [], "subsection_name": null, "type_of_material": "News"}